MedTrace Logo

Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population

NCT06444763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2026-03-06

No results posted yet for this study

Summary

This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on chronic inflammation, mobility and muscle and joint pain in an otherwise healthy population of adults over 45 years old over 10 weeks with 8 weeks supplementation.

This is PART B of the study.

Conditions

Interventions

DRUG

Maolactin

Once daily dose of 2 capsules containing a total of 500mg/day Maolactin

DRUG

Maltodextrin

Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin

Sponsors & Collaborators

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • David Briskey, PhD · RDC Clinical Pty Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2026-02-16
Completion
2026-02-16

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06444763 on ClinicalTrials.gov